Treatment of atopic dermatitis with pimecrolimus – impact on quality of life

Atopic dermatitis (AD) is a multifactorial chronic remittent skin disease which requires long-term treatment. Pimecrolimus cream 1% is a nonsteroid selective inhibitor of inflammatory cytokines and effective in the treatment of AD. Various clinical trials have shown its long-term safety and efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hae-Hyuk, Zuberbier, Torsten, Worm, Margitta
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387301/
https://www.ncbi.nlm.nih.gov/pubmed/18516272
_version_ 1782155309678067712
author Lee, Hae-Hyuk
Zuberbier, Torsten
Worm, Margitta
author_facet Lee, Hae-Hyuk
Zuberbier, Torsten
Worm, Margitta
author_sort Lee, Hae-Hyuk
collection PubMed
description Atopic dermatitis (AD) is a multifactorial chronic remittent skin disease which requires long-term treatment. Pimecrolimus cream 1% is a nonsteroid selective inhibitor of inflammatory cytokines and effective in the treatment of AD. Various clinical trials have shown its long-term safety and efficacy in pediatric and adult patients suffering from mild to moderate AD. In this article we discuss data which has assessed the impact of AD on the patient’s quality of life, and the consequent role of topical anti-inflammatory therapy for long-term AD treatment.
format Text
id pubmed-2387301
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-23873012008-05-30 Treatment of atopic dermatitis with pimecrolimus – impact on quality of life Lee, Hae-Hyuk Zuberbier, Torsten Worm, Margitta Ther Clin Risk Manag Review Atopic dermatitis (AD) is a multifactorial chronic remittent skin disease which requires long-term treatment. Pimecrolimus cream 1% is a nonsteroid selective inhibitor of inflammatory cytokines and effective in the treatment of AD. Various clinical trials have shown its long-term safety and efficacy in pediatric and adult patients suffering from mild to moderate AD. In this article we discuss data which has assessed the impact of AD on the patient’s quality of life, and the consequent role of topical anti-inflammatory therapy for long-term AD treatment. Dove Medical Press 2007-12 2007-12 /pmc/articles/PMC2387301/ /pubmed/18516272 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Lee, Hae-Hyuk
Zuberbier, Torsten
Worm, Margitta
Treatment of atopic dermatitis with pimecrolimus – impact on quality of life
title Treatment of atopic dermatitis with pimecrolimus – impact on quality of life
title_full Treatment of atopic dermatitis with pimecrolimus – impact on quality of life
title_fullStr Treatment of atopic dermatitis with pimecrolimus – impact on quality of life
title_full_unstemmed Treatment of atopic dermatitis with pimecrolimus – impact on quality of life
title_short Treatment of atopic dermatitis with pimecrolimus – impact on quality of life
title_sort treatment of atopic dermatitis with pimecrolimus – impact on quality of life
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387301/
https://www.ncbi.nlm.nih.gov/pubmed/18516272
work_keys_str_mv AT leehaehyuk treatmentofatopicdermatitiswithpimecrolimusimpactonqualityoflife
AT zuberbiertorsten treatmentofatopicdermatitiswithpimecrolimusimpactonqualityoflife
AT wormmargitta treatmentofatopicdermatitiswithpimecrolimusimpactonqualityoflife

Ejemplares similares